Conditions: Gouty Arthritis
Keywords: Gouty Gouty arthritis Gout flares Anti-interleukin-1β monoclonal antibody
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 341
Healthy volunteers: no

Brief summary:
This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all the patients, irrespective whether they have an acute flare of gout or not. Patients will be treated on demand with canakinumab (ACZ885) in this extension study.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Canakinumab
Intervention descriptions: intervention 1: None

Protocol document: